Home › Compare › TOMYY vs ABBV
TOMYY yields 0.57% · ABBV yields 3.06%● Live data
📍 TOMYY pulled ahead of the other in Year 8
Combined, TOMYY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TOMYY + ABBV for your $10,000?
TOMY Company, Ltd. plans, manufactures, and sells toys, general merchandise, card games, baby care products, etc. for infants, preschoolers, children, and adults. The company offers dolls, plastic train and rail sets, spinning tops, amusement machines, stuffed toys, and detailed replica products, as well as die-cast Japanese miniature car and robot products. It also provides baby bottles, dishes, and strollers supporting child-rearing products; card games; and licenses miscellaneous goods, and apparels and accessories. In addition, the company is involved in the content development and broadcast of BAKUGAN, PHANTOMIRAGE!, and PAW PATROL. Further, it operates a store, which offers toys, fancy goods, character merchandise, and books under the KIDDY LAND brand name. The company sells its products under approximately 60 brands, which primarily include the TRANSFORMERS, ZOIDS WILD, ANIA, POLICE X HEROINE LOVEPATRINA!, BEYBLADE BURST, DUEL MASTERS, T-ARTS, TOMYTEC, KIDDY LAND, THE FIRST YEARS, JOHN DEERE, Lamaze, BOON, TOMICA, PLARAIL, and LICCA brands. It operates in Japan, rest of Asia, Europe, Americas, and Oceania. The company was founded in 1924 and is headquartered in Tokyo, Japan.
Full TOMYY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.